GPX4 and gastric cancer: Mechanistic investigations reveal that targeting GPx4 suppresses peritoneal metastasis by inducing the accumulation of ROS, which in turn promotes RCC2 phosphorylation, ubiquitination and degradation through the activation of Aurora A. In summary, these findings uncover a previously unknown role of the GPx4-RCC2 signaling axis in the progression and metastasis of GC, identifying GPx4 as a potential therapeutic target for GC patients.